Top-Rated StocksTop-RatedNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $228.30 +0.99 (+0.43%) As of 03:32 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ascendis Pharma A/S Stock (NASDAQ:ASND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ascendis Pharma A/S alerts:Sign Up Key Stats Today's Range$225.20▼$229.0250-Day Range$223.13▼$271.1252-Week Range$186.05▼$282.15Volume483,594 shsAverage Volume698,952 shsMarket Capitalization$14.24 billionP/E Ratio17.71Dividend YieldN/APrice Target$310.75Consensus RatingBuy Company Overview Ascendis Pharma A/S is a biopharmaceutical company focused on developing therapies for rare diseases, particularly in endocrinology. The company uses its proprietary TransCon technology platform to design medicines intended to provide sustained release of therapeutic compounds and potentially improve treatment convenience and patient outcomes. Ascendis Pharma’s marketed products include Skytrofa (lonapegsomatropin-tcgb), a once-weekly growth hormone treatment for children with growth hormone deficiency, and Yorvipath (palopegteriparatide), a parathyroid hormone replacement therapy for adults with hypoparathyroidism. Skytrofa is marketed in the United States and other selected markets, while Yorvipath has received regulatory approval in the United States and Europe. The company also maintains a development pipeline addressing additional rare endocrine conditions, including investigational therapies based on its TransCon platform. Ascendis Pharma was founded in 2006 and is headquartered in Copenhagen, Denmark, with operations in the United States. Jan Mikkelsen serves as president and chief executive officer.AI Generated. May Contain Errors. Read More Ascendis Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks95th Percentile Overall ScoreASND MarketRank™: Ascendis Pharma A/S scored higher than 95% of companies evaluated by MarketBeat, and ranked 12th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 19 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialAscendis Pharma A/S has a consensus price target of $310.75, representing about 36.2% upside from its current price of $228.19.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth151.55% Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow by 151.55% in the coming year, from $3.55 to $8.93 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is 17.73, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.90.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is 17.73, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.71.Read more about Ascendis Pharma A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.59% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 4.9.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 5.74%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment-0.02 News SentimentAscendis Pharma A/S has a news sentiment score of -0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Ascendis Pharma A/S this week, compared to 6 articles on an average week.Search Interest17 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 143% compared to the previous 30 days.MarketBeat Follows8 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is an increase of 167% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have sold 64.53% more of their company's stock than they have bought. Specifically, they have bought $492,660.00 in company stock and sold $810,570.00 in company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsAscendis Pharma A/S has minimal institutional ownership at this time.Read more about Ascendis Pharma A/S's insider trading history. Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ASND Stock News HeadlinesBioMarin Pharmaceutical Inc. And Ascendis Pharma A/S Enter Into Settlement And License AgreementOctober 1 at 12:52 PM | marketscreener.comMAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Ascendis Pharma (ASND), Lakefront Biotherapeutics (LKFT) and 10x Genomics (TXG)September 30 at 1:20 PM | theglobeandmail.comFirst Look: Elon’s “Starphone”Rumors are swirling that Elon Musk is developing a new mobile device that could rival the iPhone. It's said to be thinner, longer-lasting on battery, and cheaper to produce, with the ability to work worldwide without relying on cell towers. Former Bloomberg reporter and SAC Capital trader Josh Baylin says the evidence is mounting. He notes the FCC recently gave Musk a green light connected to his mobile plans, adding fuel to speculation. Baylin previously called the smartphone boom in 2004 and predicted Apple would sell a billion phones when others expected a fraction of that.October 2 at 1:00 AM | Stansberry Research (Ad)Ascendis Pharma A/S (NASDAQ:ASND) Given Overweight Rating at Cantor FitzgeraldSeptember 28, 2026 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Stock Has Consensus Price Target of $310.75 According to AnalystsSeptember 26, 2026 | americanbankingnews.comAscendis Pharma A/S (NASDAQ:ASND) Stock Rating Lowered by Wall Street ZenSeptember 26, 2026 | americanbankingnews.comAnalysts Are Bullish on Top Healthcare Stocks: Agilent (A), Ascendis Pharma (ASND)September 22, 2026 | theglobeandmail.comMads Bodenhoff Sells 3,000 Shares of Ascendis Pharma A/S (NASDAQ:ASND) StockSeptember 10, 2026 | insidertrades.comSee More Headlines ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $213.24 at the start of the year. Since then, ASND stock has increased by 7.0% and is now trading at $228.1850. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) issued its quarterly earnings results on Friday, August, 14th. The biotechnology company reported $1.03 EPS for the quarter, missing analysts' consensus estimates of $1.71 by $0.68. The biotechnology company had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a trailing twelve-month return on equity of 32.54%. Read the conference call transcript. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an initial public offering (IPO) on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings8/14/2026Today10/02/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 4 days ago, ASND's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ASND CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees1,189Year Founded2007Price Target and Rating Average Price Target for Ascendis Pharma A/S$310.75 High Price Target$355.00 Low Price Target$255.00 Potential Upside/Downside+36.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)$12.89 Trailing P/E Ratio17.71 Forward P/E Ratio64.31 P/E GrowthN/ANet Income-$258 million Net Margins70.99% Pretax Margin8.92% Return on Equity32.54% Return on Assets7.71% Debt Debt-to-Equity Ratio0.27 Current Ratio2.99 Quick Ratio2.32 Sales & Book Value Annual Sales$814.57 million Price / Sales17.48 Cash FlowN/A Price / Cash FlowN/A Book Value($2.97) per share Price / Book-76.87Miscellaneous Outstanding Shares62,380,000Free Float37,426,000Market Cap$14.24 billion OptionableOptionable Beta0.38 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ASND) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersElon Warns "America Will Go Bankrupt". Trump's Plan Inside.National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...American Hartford Gold | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHow options let you do more with less capitalWould you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...Base Camp Trading | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | SponsoredThe end of AI data centers coming?Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...Chaikin Analytics | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
